Redefining Pet Cancer Care
Through Genomics & AI Oncology
From early detection to precision therapy — One Integrated Platform.
Every dog deserves a life where cancer is predictable, preventable, and manageable.
Why It Matters
Cancer is the leading cause of death in dogs — yet most cases are discovered only after symptoms appear.
Current diagnostics are often invasive, expensive, or unsuitable for small breeds, leaving veterinarians and owners without timely, evidence-based options.
"We address this gap with a unified approach that makes cancer care earlier, easier, and more accurate."
Late Detection
Most treatments begin when survival rates are already low.
Invasive Procedures
Biopsies are painful and stressful for pets.
High Costs
Advanced imaging and surgery are prohibitively expensive.
Our Platform
A comprehensive ecosystem predicting, detecting, and managing canine cancer from birth to end-of-life.
CancerZero Blood
Revolutionary liquid biopsy requiring just 2ml of blood.
- Detects 11 major canine cancers
- 70% Sensitivity, 95% Specificity
- Ideal for toy & small breeds
- Clinic-ready reports
CancerZero Tissue
Deep genomic analysis for informed treatment decisions.
- Whole-gene tumor profiling
- Identifies actionable mutations
- Supports targeted therapy selection
- Data-driven treatment plans
EgoPet Genomics
Genetic insights connecting preventative care to oncology.
- Breed ancestry analysis
- Genetic disease risk profiling
- Personalized diet & wellness
- Preventive care ecosystem
- Gene-based nutritional
What Makes Us Different
A Unified Journey No Competitor Can Match
Most companies offer only one part of the cancer-care pipeline: breed DNA testing, liquid biopsy, or tumor sequencing. GenesisEgo is the only company that integrates the entire lifecycle.
This creates a continuous, defensible data loop that follows the same dog throughout its life — an advantage unmatched in today's veterinary market.
Science-Backed. Patented. Clinically Validated.
Deep Learning
Proprietary deep-learning models for cancer-derived fragment analysis.
Global IP Portfolio
2025 Patent (PCT, CN, KR, JP)
: Device and Method for Predicting Patellar Luxation in Companion Dogs Using Artificial Intelligence Model
2023 Patent (PCT)
: Device for Discriminating Cancer Using Deep Learning Algorithm
2022 Patent (EU, KR, JP Registered)
: Appartus and Method for Diagnosing a Cancer Using Liquid Biopsy DATA
Growing Data Asset
Growing dataset of canine genomic & cancer profiles.
Recent Publications
- 2025 - Frontiers in Veterinary Science Early detection of canine hemangiosarcoma via cfDNA fragmentation and copy number alterations in liquid biopsies using machine learning
- 2024 - Frontiers in Veterinary Science Advancing the early detection of canine cognitive dysfunction syndrome with machine learning-enhanced blood-based biomarkers
- 2024 - Journal of Translational Medicine DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells
- 2022 - Journal of Cellular Physiology Sclerostin aggravates insulin signaling in skeletal muscle and hepatic steatosis via upregulation of ER stress by mTOR‐mediated inhibition of autophagy under hyperlipidemic conditions
A Massive, Under-Served Global Market
Perfect Timing for Data-Driven Pet Oncology
Projected to reach $428B by 2032 driven by pet humanization.
Insurers actively seeking data-backed solutions for risk management.
Canine oncology alone generated $1.35B in 2024.
Current Fundraising
Raising $3,000,000 USD to accelerate productization and US/Global market entry.
Tailored Solutions
Select your area of interest
Multi-Layer Revenue Model
Diagnostics
CancerZero Blood & Tissue, EgoPet genomics sold via hospitals and online channels.
Subscription
Personalized diet & wellness programs generating continuous recurring revenue.
Data Partnerships
APIs and white-label services for insurers and pet-health companies.
Roadmap to Global Scale
- 2025: Commercial launch across Korea & Asia
- 2026-2027: U.S. market entry and expansion of subscription ecosystem
